Current evidence for the hepatoprotective activities of the medicinal mushroom Antrodia cinnamomea

Chinese Medicine (United Kingdom)

Volumn 8, Issue 1, 2013, Pages

  Yue, Patrick Ying Kit ^a   Wong, Yi Yi ^a   Wong, Kay Yuen Ki ^a   Tsoi, Yeuk Ki ^a   Leung, Kelvin Sze Yin ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTCIN A; ANTCIN B; ANTCIN C; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; ANTRODIA CINNAMOMEA EXTRACT; ANTRODIN A; ANTRODIN B; ANTRODIN C; ANTRODIN D; ANTRODIN E; ANTROQUINONOL; BEVACIZUMAB; CHINESE DRUG; CISPLATIN; ERLOTINIB; GEFITINIB; GINSENOSIDE; HERBACEOUS AGENT; INDIRUBIN; METHYL ANTCINATE A; METHYL ANTCINATE B; PLANT EXTRACT; POLYSACCHARIDE; SINOMENINE; UNCLASSIFIED DRUG;

ALCOHOL LIVER DISEASE; ALCOHOL METABOLISM; ALCOHOLIC FATTY LIVER; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ANTRODIA CINNAMOMEA; APOPTOSIS; BLEEDING; CANCER INCIDENCE; CANCER MORTALITY; CELL CYCLE ARREST; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG PURIFICATION; DRUG SAFETY; ENZYME INHIBITION; HAIR LOSS; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER PROTECTION; MEDICINAL MUSHROOM; NONHUMAN; PATHOGENESIS; REVIEW;

EID: 84887143773     PISSN: None     EISSN: 17498546     Source Type: Journal    
DOI: 10.1186/1749-8546-8-21     Document Type: Review

References (93)

1. Chen CJ, Su CH, Lan MH. Study on solid cultivation and bioactivity of Antrodia camphortaa. Fungal Sci 2001, 16:65-72.
2. Zang M, Su CH. Ganoderma comphoratum, a new taxon in genus Ganderma from Taiwan, China. Acta Bot Yunnanica 1990, 12:395-396.
3. Phuong do T, Ma CM, Hattori M, Jin JS. Inhibitory effects of antrodins A-E from Antrodia cinnamomea and their metabolites on hepatitis C virus protease. Phytother Res 2009, 23:582-584. 10.1002/ptr.2657, 19003946.
4. Chen YS, Pan JH, Chiang BH, Lu FJ, Sheen LY. Ethanolic extracts of Antrodia cinnamomea mycelia fermented at varied times and scales have differential effects on hepatoma cells and normal primary hepatocytes. J Food Sci 2008, 73:H179-H185. 10.1111/j.1750-3841.2008.00884.x, 18803715.
5. Ryder SD, Beckingham IJ. ABC of diseases of liver, pancreas, and biliary system: acute hepatitis. BMJ 2001, 322:151-153. 10.1136/bmj.322.7279.151, 1119417, 11159575.
6. Matheny SC, Kingery JE. Hepatitis A. Am Fam Physician 2012, 86:1027-1034.
7. Conjeevaram HS, Lok AS. Management of chronic hepatitis B. J Hepatol 2003, 38:S90-S103.
8. Perrillo RP. Management of the patient with hepatitis B virus-related cirrhosis. J Hepatol 2003, 39:S177-S180.
9. Chisari FV. Rous-Whipple award lecture. Viruses, immunity, and cancer: lessons from hepatitis B. Am J Pathol 2000, 156:1117-1132. 10.1016/S0002-9440(10)64980-2, 1876872, 10751335.
10. Mulkay JP. Hepatitis B: screening and treatment. Rev Med Brux 2012, 33:215-222.
11. Peppa D, Maini MK. Pathogenesis of hepatitis B virus infection and potential for new therapies. Br J Hosp Med (Lond) 2012, 73:581-584.
12. Cohen J. Report of new hepatitis virus has researchers intrigued and upset. Science 1999, 285:644-645. 10.1126/science.285.5428.644, 10454907.
13. Cohen J. The scientific challenge of hepatitis C. Science 1999, 285:26-30. 10.1126/science.285.5424.26, 10428695.
14. Terilli RR, Cox AL. Immunity and hepatitis C: a review. Curr HIV/AIDS Rep 2013, 10:51-58.
15. Bouchard MJ, Navas-Martin S. Hepatitis B and C virus hepatocarcinogenesis: lessons learned and future challenges. Cancer Lett 2011, 305:123-143. 10.1016/j.canlet.2010.11.014, 3071446, 21168955.
16. Lee IH, Huang RL, Chen CT, Chen HC, Hsu WC, Lu MK. Antrodia camphorata polysaccharides exhibit anti-hepatitis B virus effects. FEMS Microbiol Lett 2002, 209:63-67. 10.1111/j.1574-6968.2002.tb11110.x, 12007655.
17. Huang RL, Huang QL, Chen CF, Chang TT, Chou CJ. Anti-viral effects of active compounds from Antrodia camphorata on wild-type and lamivudine-resistant mutant HBV. Chin Pharmaceut J 2003, 55:371-379.
18. Popper H, Thung SN, Gerber MA. Pathology of alcoholic liver diseases. Semin Liver Dis 1981, 1:203-216. 10.1055/s-2008-1041748, 6287646.
19. Schaff Z, Székely E, Járay B, Kiss A. Pathology of liver tumors. Orv Hetil 2004, 145:368-374.
20. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: globocan 2000. Int J Canc 2001, 94:153-156.
21. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Canc 2001, 37:S4-S66.
22. Chen JG, Zhu J, Parkin DM, Zhang YH, Lu JH, Zhu YR, Chen TY. Trends in the incidence of cancer in Qidong, China. 1978-2002. Int J Canc 2006, 119:1447-1454.
23. Deuffic S, Poynard T, Buffat L, Valleron AJ. Trends in primary liver cancer. Lancet 1998, 351:214-215.
24. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999, 340:745-750. 10.1056/NEJM199903113401001, 10072408.
25. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003, 139:817-823. 10.7326/0003-4819-139-10-200311180-00009, 14623619.
26. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979-94. Lancet 1997, 350:1142-1143.
27. Wong CM, Ng IO. Molecular pathogenesis of hepatocellular carcinoma. Liver Int 2008, 28:160-174.
28. Idilman R, De Maria N, Colantoni A, Van Thiel DH. Pathogenesis of hepatitis B and C-induced hepatocellular carcinoma. J Viral Hepat 1998, 5:285-299. 10.1046/j.1365-2893.1998.00116.x, 9795912.
29. WHO Surveillance and response: WHO. Hepatitis B 2002, Department of communable diseases, WHO.
30. Moradpour D, Blum HE. Pathogenesis of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2005, 17:477-483. 10.1097/00042737-200505000-00002, 15827436.
31. Gomaa AI, Khan SA, Toledano MB, Waked SD. Taylor-Robinson, hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008, 14:4300-4308. 10.3748/wjg.14.4300, 2731180, 18666317.
32. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Canc 2006, 6:674-687.
33. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991, 350:429-431. 10.1038/350429a0, 1672732.
34. Riley J, Mandel HG, Sinha S, Judah DJ, Neal GE. In vitro activation of the human Harvey-ras proto-oncogene by aflatoxin B1. Carcinogenesis 1997, 18:905-910. 10.1093/carcin/18.5.905, 9163674.
35. Aguilar F, Harris CC, Sun T, Hollstein M, Cerutti P. Geographic variation of p53 mutational profile in nonmalignant human liver. Science 1994, 264:1317-1319. 10.1126/science.8191284, 8191284.
36. Ozturk M. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 1991, 338:1356-1359. 10.1016/0140-6736(91)92236-U, 1682737.
37. Hoek JB, Pastorino JG. Ethanol, oxidative stress, and cytokine-induced liver cell injury. Alcohol 2002, 27:63-68. 10.1016/S0741-8329(02)00215-X, 12062639.
38. McClain CJ, Hill DB, Song Z, Deaciuc I, Barve S. Monocyte activation in alcoholic liver disease. Alcohol 2002, 27:53-61. 10.1016/S0741-8329(02)00212-4, 12062638.
39. Campbell JS, Hughes SD, Gilbertson DG, Palmer TE, Holdren MS, Haran AC, Odell MM, Bauer RL, Ren HP, Haugen HS, Yeh MM, Fausto N. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci USA 2005, 102:3389-3394. 10.1073/pnas.0409722102, 552940, 15728360.
40. Parikh S, Hyman D. Hepatocellular cancer: a guide for the internist. Am J Med 2007, 120:194-202. 10.1016/j.amjmed.2006.11.020, 17349437.
41. Ribatti D, Vacca A, Dammacco F. The role of the vascular phase in solid tumor growth: a historical review. Neoplasia 1999, 1:293-302. 10.1038/sj.neo.7900038, 1508099, 10935483.
42. Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J Hepatol 2004, 41:864-880. 10.1016/j.jhep.2004.09.006, 15519663.
43. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Canc 2003, 3:401-410.
44. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257. 10.1038/35025220, 11001068.
45. Sugimachi K, Tanaka S, Terashi T, Taguchi K, Rikimaru T, Sugimachi K. The mechanisms of angiogenesis in hepatocellular carcinoma: angiogenic switch during tumor progression. Surgery 2002, 131:S135-S141. 10.1067/msy.2002.119365, 11821800.
46. Hsu YL, Kuo YC, Kuo PL, Ng LT, Kuo YH, Lin CC. Apoptotic effects of extract from Antrodia camphorata fruiting bodies in human hepatocellular carcinoma cell lines. Canc Lett 2005, 221:77-89.
47. Hsu YL, Kuo PL, Cho CY, Ni WC, Tzeng TF, Ng LT, Kuo YH, Lin CC. Antrodia cinnamomea fruiting bodies extract suppresses the invasive potential of human liver cancer cell line PLC/PRF/5 through inhibition of nuclear factor kappaB pathway. Food Chem Toxicol 2007, 45:1249-1257. 10.1016/j.fct.2007.01.005, 17316946.
48. Kuo PL, Hsu YL, Cho CY, Ng LT, Kuo YH, Lin CC. Apoptotic effects of Antrodia cinnamomea fruiting bodies extract are mediated through calcium and calpain-dependent pathways in Hep 3B cells. Food Chem Toxicol 2006, 44:1316-1326. 10.1016/j.fct.2006.02.009, 16600460.
49. Hsieh YC, Rao YK, Whang-Peng J, Huang CY, Shyue SK, Hsu SL, Tzeng YM. Antcin B and its ester derivative from Antrodia camphorata induce apoptosis in hepatocellular carcinoma cells involves enhancing oxidative stress coincident with activation of intrinsic and extrinsic apoptotic pathway. J Agric Food Chem 2011, 59:10943-110954. 10.1021/jf202771d, 21916504.
50. Hsieh YC, Rao YK, Wu CC, Huang CY, Geethangili M, Hsu SL, Tzeng YM. Methyl antcinate A from Antrodia camphorata induces apoptosis in human liver cancer cells through oxidant-mediated cofilin- and Bax-triggered mitochondrial pathway. Chem Res Toxicol 2010, 23:1256-1267. 10.1021/tx100116a, 20557081.
51. Lee TH, Lee CK, Tsou WL, Liu SY, Kuo MT, Wen WC. A new cytotoxic agent from solid-state fermented mycelium of Antrodia camphorate. Planta Med 2007, 73:1412-1415. 10.1055/s-2007-990232, 17932820.
52. Chiang PC, Lin SC, Pan SL, Kuo CH, Tsai IL, Kuo MT, Wen WC, Chen P, Guh JH. Antroquinonol displays anticancer potential against human hepatocellular carcinoma cells: a crucial role of AMPK and mTOR pathways. Biochem Pharmacol 2010, 79:162-171. 10.1016/j.bcp.2009.08.022, 19723512.
53. Song TY, Hsu SL, Yen GC. Induction of apoptosis in human hepatoma cells by mycelia of Antrodia camphorata in submerged culture. J Ethnopharmacol 2005, 100:158-167. 10.1016/j.jep.2005.02.043, 15949907.
54. Song TY, Hsu SL, Yeh CT, Yen GC. Mycelia from Antrodia camphorata in Submerged culture induce apoptosis of human hepatoma HepG2 cells possibly through regulation of Fas pathway. J Agric Food Chem 2005, 53:5559-5564. 10.1021/jf050329+, 15998114.
55. Lin YW, Chiang BH. 4-acetylantroquinonol B isolated from Antrodia cinnamomea arrests proliferation of human hepatocellular carcinoma HepG2 cell by affecting p53, p21 and p27 levels. J Agric Food Chem 2011, 59:8625-8631. 10.1021/jf2011326, 21739974.
56. Lin YW, Pan JH, Liu RH, Kuo YH, Sheen LY, Chiang BH. The 4-acetylantroquinonol B isolated from mycelium of Antrodia cinnamomea inhibits proliferation of hepatoma cells. J Sci Food Agric 2010, 90:1739-1744. 10.1002/jsfa.4010, 20564437.
57. Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Pérez JM. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem 2007, 7:3-18. 10.2174/187152007779314044, 17266502.
58. Jordan P, Carmo-Fonseca M. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 2000, 57:1229-1235. 10.1007/PL00000762, 11028915.
59. Ribatti D, Vacca A, Nico B, Sansonno D, Dammacco F. Angiogenesis and anti-angiogenesis in hepatocellular carcinoma. Canc Treat Rev 2006, 32:437-444.
60. Pang R, Poon RT. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Canc Lett 2006, 242:151-167.
61. Finn RS, Zhu AX. Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Rev Anticancer Ther 2009, 9:503-509. 10.1586/era.09.6, 19374603.
62. Chen SC, Lu MK, Cheng JJ, Wang DL. Antiangiogenic activities of polysaccharides isolated from medicinal fungi. FEMS Microbiol Lett 2005, 249:247-254. 10.1016/j.femsle.2005.06.033, 16046081.
63. Yang CM, Zhou YJ, Wang RJ, Hu ML. Anti-angiogenic effects and mechanisms of polysaccharides from Antrodia cinnamomea with different molecular weights. J Ethnopharmacol 2009, 123:407-412. 10.1016/j.jep.2009.03.034, 19501273.
64. Cheng JJ, Huang NK, Chang TT, Wang DL, Lu MK. Study for anti-angiogenic activities of polysaccharides isolated from Antrodia cinnamomea in endothelial cells. Life Sci 2005, 76:3029-3042. 10.1016/j.lfs.2004.11.023, 15850596.
65. Chan YK, Kwok HH, Chan LS, Leung KS, Shi J, Mak NK, Wong RN, Yue PY. An indirubin derivative, E804, exhibits potent angiosuppressive activity. Biochem Pharmacol 2012, 83:598-607. 10.1016/j.bcp.2011.12.003, 22178720.
66. Yue PY, Mak NK, Cheng YK, Leung KW, Ng TB, Fan DT, Yeung HW, Wong RN. Pharmacogenomics and the Yin/Yang actions of ginseng: anti-tumor, angiomodulating and steroid-like activities of ginsenosides. Chin Med 2007, 2:42-62.
67. Leung KW, Yung KK, Mak NK, Yue PY, Luo HB, Cheng YK, Fan TP, Yeung HW, Ng TB, Wong RN. Angiomodulatory and neurological effects of ginsenosides. Curr Med Chem 2007, 14:1371-1380. 10.2174/092986707780597916, 17504218.
68. Yue PY, Wong DY, Wu PK, Leung PY, Mak NK, Yeung HW, Liu L, Cai Z, Jiang ZH, Fan TP, Wong RN. The angiosuppressive effects of 20(R)-ginsenoside Rg3. Biochem Pharmacol 2006, 72:437-445. 10.1016/j.bcp.2006.04.034, 16793023.
69. Fan TP, Yeh JC, Leung KW, Yue PY, Wong RN. Angiogenesis: from plants to blood vessels. Trends Pharmacol Sci 2006, 27:297-309. 10.1016/j.tips.2006.04.006, 16697473.
70. Kok TW, Yue PY, Mak NK, Fan TP, Liu L, Wong RN. The anti-angiogenic effect of sinomenine. Angiogenesis 2005, 8:3-12. 10.1007/s10456-005-2892-z, 16132613.
71. Charels K, Klöppel G. Pathology and pathogenesis of toxic (alcoholic) liver disease. Hepatogastroenterology 1991, 38:189-194.
72. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans Personal habits and indoor combustions. Volume 100 E. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum 2012, 100:1-538. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans.
73. Yip WW, Burt AD. Alcoholic liver disease. Semin Diagn Pathol 2006, 23:149-160. 10.1053/j.semdp.2006.11.002, 17355088.
74. Doria JJ. Alcohol metabolism. Alcohol Health Res World 1997, 21:323.
75. Bode C, Bode JC. Alcohol absorption, metabolism, and production in the gastrointestinal tract. Alcohol Health Res World 1997, 21:82-83.
76. Zakhari S. Overview: How is alcohol metabolized by the body?. Alcohol Res Health 2006, 29:245-254.
77. Lieber CS. Hepatic, metabolic and toxic effects of ethanol: 1991 update. Alcohol Clin Exp Res 1991, 15:573-592. 10.1111/j.1530-0277.1991.tb00563.x, 1928631.
78. Lieber C. The discovery of the microsomal ethanol oxidizing system and its physiologic and pathologic role. Drug Metab Rev 2004, 36:511-529. 10.1081/DMR-200033441, 15554233.
79. Donohue TM. Alcohol-induced steatosis in liver cells. World J Gastroenterol 2007, 13:4974-4978.
80. Sozio M, Crabb DW. Alcohol and lipid metabolism. Am J Physiol Endocrinol Metab 2008, 295:E10-E16. 10.1152/ajpendo.00011.2008, 2493591, 18349117.
81. Bruha R, Dvorak K, Petrtyl J. Alcoholic liver disease. World J Hepatol 2012, 4:81-90. 10.4254/wjh.v4.i3.81, 3321494, 22489260.
82. Syn WK, Teaberry V, Choi SS, Diehl AM. Similarity and differences in the pathogenesis of alcoholic and non-alcoholic steatohepatiotis. Semin Liver Dis 2009, 29:200-210. 10.1055/s-0029-1214375, 3644873, 19387919.
83. Fernández-Checa JC, Kaplowitz N, Colell A, García-Ruiz C. Oxidative stress and alcoholic liver disease. Alcohol Health Res World 1997, 21:321-324.
84. Lieber CS. Alcohol, liver, and nutrition. J Am Coll Nutr 1991, 10:602-632. 10.1080/07315724.1991.10718182, 1770192.
85. Wu MT, Tzang BS, Chang YY, Chiu CH, Kang WY, Huang CH, Chen YC. Effects of Antrodia camphorata on alcohol clearance and antifibrosis in livers of rats continuously fed alcohol. J Agric Food Chem 2011, 59:4248-4254. 10.1021/jf104561h, 21401100.
86. Lu ZM, Tao WY, Zou XL, Fu HZ, Ao ZH. Protective effects of mycelia of Antrodia camphorata and Armillariella tabescens in submerged culture against ethanol-induced hepatic toxicity in rats. J Ethnopharmacol 2007, 110:160-164. 10.1016/j.jep.2006.09.029, 17092673.
87. Lu ZM, Tao WY, Xu HY, Ao ZH, Zhang XM, Xu ZH. Further studies on the hepatoprotective effect of Antrodia camphorata in submerged culture on ethanol-induced acute liver injury in rats. Nat Prod Res 2011, 25:684-695. 10.1080/14786410802525487, 20623423.
88. Hsiao G, Shen MY, Lin KH, Lan MH, Wu LY, Chou DS, Lin CH, Su CH, Sheu JR. Antioxidative and hepatoprotective effects of Antrodia camphorata extract. J Agric Food Chem 2003, 51:3302-3308. 10.1021/jf021159t, 12744658.
89. Kumar KJ, Chu FH, Hsieh HW, Liao JW, Li WH, Lin JC, Shaw JF, Wang SY. Antroquinonol from ethanolic extract of mycelium of Antrodia cinnamomea protects hepatic cells from ethanol-induced oxidative stress through Nrf-2 activation. J Ethnopharmacol 2011, 136:168-177. 10.1016/j.jep.2011.04.030, 21540101.
90. Lin WC, Kuo SC, Lin WL, Fang HL, Wang BC. Filtrate of fermented mycelia from Antrodia camphorata reduces liver fibrosis induced by carbon tetrachloride in rats. World J Gastroenterol 2006, 12:2369-2374.
91. Song TY, Yen GC. Protective effects of fermented filtrate from Antrodia camphorata in submerged culture against CCl4-induced hepatic toxicity in rats. J Agric Food Chem 2003, 51:1571-1577. 10.1021/jf0209701, 12617586.
92. Huang CH, Chang YY, Liu CW, Kang WY, Lin YL, Chang HC, Chen YC. Fruiting body of Niuchangchih (Antrodia camphorata) protects livers against chronic alcohol consumption damage. J Agric Food Chem 2010, 58:3859-3866. 10.1021/jf100530c, 20192205.
93. Dai YY, Chuang CH, Tsai CC, Sio HM, Huang SC, Chen JC, Hu ML. The proliferation of Anthrodia camphorate against acute hepatotoxicity of alcohol in rat. J Food Drug Ann 2003, 11:177-185.